Data from secondary progressive multiple sclerosis patient treated with intranasal treatment with foralumab will be presented at the consortium of multiple sclerosis centers (cmsc) 2022 annual meeting

New york, june 01, 2022 (globe newswire) -- tiziana life sciences (nasdaq:  tlsa ) ("tiziana" or the "company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced that dr. tanuja chitnis, md, professor of neurology and the principal investigator of the clinical study at the at the brigham and women's hospital (bwh), boston, ma., will be presenting a poster discussing clinical data from a patient with secondary progressive multiple sclerosis (spms), who was treated with intranasal foralumab for six months.
TLSA Ratings Summary
TLSA Quant Ranking